<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the role and mechanism of catalpol in brain <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in a rat model of <z:hpo ids='HP_0001297'>stroke</z:hpo>, the effect of catalpol (5 mg/kg; i.p) or vehicle administered 24 hours after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (pMCAO) on behavior, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, ultra-structural integrity of brain capillary endothelial cells, and expression of EPO and VEGF were assessed </plain></SENT>
<SENT sid="1" pm="."><plain>Repeated treatments with Catalpol reduced neurological deficits and significantly improved <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, while significantly increasing brain levels of EPO and VEGF without worsening <z:chebi fb="2" ids="33602">BBB</z:chebi> <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>These results suggested that catalpol might contribute to infarcted-brain <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and ameliorate the <z:hpo ids='HP_0000969'>edema</z:hpo> of brain capillary endothelial cells (BCECs) by upregulating VEGF and EPO coordinately </plain></SENT>
</text></document>